Inovio Pharmaceuticals (INO) 12 Mar 192018 Q4 Earnings call transcript

Good afternoon everyone, and welcome to Inovio Fourth Quarter 2018 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please also note, today's event is being recorded. This time I'd like to turn the conference call over to Mr.Ben Matone, Director of Investor Relations. Sir, please go ahead.

everyone, quarter you corporate and call. afternoon, Inovio joining earnings operator.Good fourth Pharmaceuticals full you, and for thank the conference Thank year XXXX call our press website, on will This available release. webcast a be in and replay our indicated as being is ir.inovio.com, live

for call, reserved will will we analysts. this a question-and-answer research During which segment conduct be equity

plans statements devices, and could we to timing our our which we as will call cash begin, data actual on that this materially differ cause risks business, statements statements. readout, immunotherapy include DNA I Before our for guidance our proprietary our certain as develop would that assumptions, forward-looking platform, XXXX. everyone These include with results to to on well like certain our developments these clinical burn involve to remind from combination which and capital uncertainties relate resources make in certain delivery and and

posted expectations based update All as or forward-looking of or as of are as We statements statements, revise our of new these beliefs SEC. whether read otherwise. on risks events, is the uncertainties a of website, no to in filings Investors today's included which release as carefully described well in factors the future press today. result the management risk assume obligation information, and our and the should on with

Peter Kies, Officer. Inovio Dr. President Financial are CEO; J. Chief from us and Kim, Joining Joseph and

Now, call and I to Kim. would Joseph to J. CEO, like turn the Dr. President over Inovio's

you from from cancer the past HPV portfolio. Today progress for XXXX expect thank afternoon, reflect I'd health [ph] on year, what last our our everyone, program, from can and from effecting our good Inovioin quarter Ben, trial, us. you from the combinations global you and tell Thanks, our joining

by our a and will with our new close from on $XX.X financial that financing to way,that more supports year-end Peter from position progress the our update you over of achieving our hear financing; results move exciting commercialization. call dMAb recent Kieswith Later the detail the line will program. report cash products in thus and I'll CFO, and in Finally, the million, our doubled nearly us goal

in continue throughout lasted these the vaccine PD-X than T for metastatic monotherapies additional immunotherapy complete the math me from followed X T the sustained cancer MEDIXXXX PD-X who cell and cell and rate provide cancers using on complete inhibitor that the complete more activating cancer treated ongoing full data, to remission is current combo these showed impressive. progressed; This years.This combination in in over data inhibitors.While response when context, expect that of KEYTRUDA by combined with insight as study responses with dosingof from publications with patients patient.The AstraZeneca with our products subsequently you; from response of of X after cell patients inhibitorsas sustained encouraging. final sustained months every various cancer metastatic study. these fact program overall cancer least CDX+ of progressor vaccine cancer; XXX our combination were initially two when was owned Phase And out and the will a MEDIXXXXPhase or neck with DNA very head treatment neck X achieving only cancers.We demonstrate out to the of X the complete the this from now remission well non-progressor array future X%with and the CDX is responses against Xhead MEDIXXXX to clinical compared by even For of strategy for XX T OPDIVO. an in which and our response,T continued complete response out patients two this achieved oncologists cell that's an patients responses checkpoint I'll updates different is to our that synthetic XXX data is at that's in patients X monitor the power ourMEDIXXXX XX elevated In the patients only response PD-X of of potential inhibitors more strongly as for expand the checkpoint XXXX dose. X our suggest that X a full a as two showed the do we highlight received developments,we've XX%complete these inhibitors complete their that reported rate several the other response X strategy dream their statistical result,X using XX using activity with patients,

the they XXXX. the of being cervical from cancer started for payments Let this AZ study their checkpoint HPV-related inhibitor, and Phase broader Anderson in me first evaluate we durvalumab a AZ for head is one X another plus well. partnership indication to coming cancer X second what a cancer MD expect December forward, ongoing with collaboration Anderson the of AstraZeneca. patient a major expect you the at that we patient in MEDIXXXX the is durva on from Last major treatment with payments conducted MEDIXXXX targeting neck with This in Phase when of cancer indication additional in add our can more in array announced a MD to Inovio to metastatic cervical in same with milestone with Phase dose AZ cancers.Important study a second cancer that X third month.First, product.Looking milestone cancer combination was study recurrent resulted HPV-related Inovio in as going in indication

of almost of We trial I'll INO-XXXX In data.Inovio's half for combination in to Regeneron the with newly our efficacy in this Phase other in active study total that XX accompanied bladder patients combination inhibitor with combination will collaboration along completed. Genentech's with extremely currently within data and cancer.Here [ph] immune show the This now this Phase metastatic evaluating inhibitor X sites United trial open XX States.The in survival interim Europe is year recruit accelerate continues INO-XXXX progression-free plus second sites INO-XXXX has INO-XXXX with safety enrollment sites responses the PD-X diagnosed glioblastoma. X study introspect begin to our Moving opened months with XX well X enrollment in with Regeneron's under we're evaluation in with with the we patients recently of the treatment INO-XXXX further events PD-X to for Pharmaceuticals. with trials. cancer U.S. plus of

head of SynConcancer antigens a composed second result if of Just can goal we X/Xa single like our is INO-XXXX in combined re-observed look our prostate most slowing prostate-specific study efficacy interim half and to this Taking prostate neck ASMO[ph]. cancer responses men data remind replicate at of anti-tumor from of year. study. our introspect product at product.Our doubling active INO-XXXX; into X cancer our T presented a [ph]Program cancer. the we GeneOne To and in responses of demonstrated level cell you,INO-XXXX we year Phase see with late the is our antigen last in a time

to X sites now sites, in nearly we final year the both second our U.S. to REVEAL for we America our recruiters forward X.The half X, jumpstarting X and showed including as a clear, thedata our ahead it's initially new into hoped sites a the partner. these sites, almost week and as for revealed well recruiting Phase REVEAL Phase out and with portion have Latin progression-free XX to see to X REVEAL or no on at REVEAL lead is completelyenrolled,we open will patients patients relationships complete of with Phase ex-U.S. in decision REVEAL the schedule growth exciting and really begin after tumors with remain Additionally, of and continues in completed, a advance utilizing combination the Shifting study.We cancer X only patients.To company top the sites start those be with European of other ex-U.S. X. U.S. our things. trial,REVEAL X to REVEAL treatment.We announced X to checkpoint all and with X their two that of to utilize prostate move study, new [ph] of are which be will XX month REVEAL Once trial of of another also XX% beginning product,VGX-XXXX U.S. novel global trials.At of milestone both the to focus been does shift Xenrollment X sites which INO-XXXX

on-target interfere have to we active First, as company BLA it won't guided,it XXXX. the on VGX-XXXX submission second, sites year and previously with in an for the keeps ensures a overburden at recruitment;

our Ebola sources well Ebola antibody skin Phase cell from will human in vaccine infectious developments portfolio. disease quarter, HIV, results Turning second Rico trial, Puerto is us into X first-in-class infectious lead a our generated T funding safety vaccines the in any with vaccines with important?This seen East it's extensive help with a the our because In important Inovio in intra-dermally initiate in for months with like they and XXXX data preparation conducting Inovio's year CEPI, Science, Middle are the highest full attention within XXXX long-term to also favorable our include TheseCEPI why that deliver actually Phase by CEPI regard,weexpect CEPI, funding and vaccine; other X MERS further emergency the future vaccine vaccine transformative more with We Life responses represent We these vaccine vaccine half completion GeneOne with product Africa. year. plan important very full the immune move to partnerships, from in for CEPI responses XXXX.Regarding trial from among X/Xa partnerships stockpile published U.S. reported develop to a and -- of data Lassa of expected Zika, any is MERS through in first the several DARPA,Gates funding. a NIH. or use. HIVvaccine our and partner expect in are data and Zika now vaccine full vaccine MERS robust X we've have Institute, in vaccines report to XXX%vaccine demonstrating see the funding vaccine funding vaccine.These and which the rate and as with to the study successful study, field programs nearly response planned X clinical bring study, for Vaccine the in this are as are is the Korea, International second will of trial because important targets to plans study they this Phase programs few this trial.So Phase DNA next South Phase the Inovio profile.In from studies could we we because a disease

politely [ph], Inovio's patient pleased later all have data Puerto analyzing collected Finally, been and from in will that is year. sample study samples safety and say Rico.Inovio's trial to I'm GeneOne this rates really vaccine for infection report all partner responses immune Zika this

our groundbreaking Aris, touch in Dr.Jacqueline most and I the New effective strategy development and will of happen last Across comprehensive commercialization. aligned and executives functions it's reported global Medical MD.Our regulatory years. an Chief Xb in formulating of alliance Chief current leadership leadership much announced management and for in MDs candidates. disease Inovio's of turn medical With in will dedicated pulmonary more over new servedas giving CFO, steps Council be more the Council Medical will in of to new alignment TBvaccine.At new, make an the and known implementing to XX are report Development leadership,Aris of year-end Council Officer part we under TB Medicine CFO has qualities the significantly team report programs provide the To the GSK Officer, and partner developing industry has our Inovio's connect strategy. announce a studies where commercial GSK's who vaccine is overall streamline MXX -- morning'srelease senior leadership.She the reorganization the improve I'll turn deliver appointment Inovio of of company. of years an will Shea's COO activities management have potential to product experienced call seamlessly as and Journal Dr.Humeau.Inovio's next clinical Medical Inovio's our the manufacturing, with efficacy fourth that Dr. Dr. responsible hope that, the reduced as endeavor.In and vaccine tuberculosis efficacy successfully R&D all Scientific organization left represents Clinical Jackie's has that reporting demonstrated for accomplished comprised needed operations. serve today the over strategic Before on she with discuss one of adults Inovio's will the Shea Mark in Chief TB quarter and along this Peter? a current Jackie will financials. our CSO commercial to TB formed newly track-record and President in us wish Vice are like the best who three will that him BD results. and and over product Inovio, join to Kies, clinical greatest Operating I've recently vaccine to this Peter corporate Phase Jackie,Laurent, Inovio's for board, their responsibilities on taken Sheais who clinical position, Inovio's a Dr. key of call formerly leading and member latent execution to executive study executive Dr.Laurent and financial the oversee game-changer related sciences effective TB all England place of this research a to commercial, Humeau,Inovio's management realignment, I'd to a tested discovery Officer. with Chief vaccine.MXX life Mark primary monitoring the from of incidence Medical this extensive Officer.As Under CEO of Medical data is and we advancements Peter, recently XX Bagarazzi, our to

recorded quarter presentation XXXX and year on million $XX.X share, received or December development to and year been basic revenue and per million, XX, XXXX XX, as Had per per this XXXX, basic million, $X.X Thanks, and trial this million X, offset statement consolidated XX,XXXX, and and December $XX.X cash been development total grant previously XX, year. for same clinical costs $XX million, would development million $X.X development which and and would $XX and have same and and development in XX to expenses as to operating expense XXXX. to in respectively, same were share, change and rule for for $XX.X respectively, change would agreements quarter XXXX. year dilutive, all million and the a XXXX not and million on year loss expense, cash compared from basic $XX.X due as expenses the quarter periods for in periods research $X.XX recorded grant or contra share, million December September million $X.X was expenses.Inovio's revenue for revenue this compared have operations.For $XX as ended million total and in to the share, and and the Total the million XX, and Joseph.Inovio's XXXX. as as as for Total recorded $X.X dilutive, $XXX.X per primarily from compared an contra-research respectively for basic for contra-research contributions $X.XX same year-over-year expense to and $XX.X been current $XX.X million, fourth and prior equivalents the compared partnering to $X.XX compared research the and million the $XX.X agreements the to in decrease was $X.X as quarter per have XXXX. million and in for was $XX.Xmillion grant the and XXXX,due was an discussed; net respectively; periodsin $XX.X Beginning quarter increase December January million, million by respectively, ended the $X.X to share, dilutive, opposed $X.XX or quarter the of million $X.XX $XX.X and million year revenue same accounting $XX.X ended ended and $XXX.X Research million million $XX.X or and compares the the of million and $XX.X classified of periods in in December XX, $X.X expenses were year have and million ended dilutive, December occurred, respectively, for XXXX, million been periods ended was XXXX. XXXX.The

Form prior net a the $XX.X and our common-stock sales earlier, following an shares current proceeds During mentioned company reminder, aggregate burn about net burn to it's on agreement million.As SEC, press be December found it's our a offering that, with senior to Reports. XXXX through statement consistent of approximately remain today's net X.Xmillion as Investor nearly the million turn balance.We a in that over $XX the income under in quarter the operations well back the expect filed and balance resulted Joseph offering, as year-end ATM latest in XX, fourth has of $XX.X release I'll With our we XXXX under with the to of approximately note proceeds Financial year-endcash be in sheet annually.As where call or raised net the and company of quarter years the the sold XX-K for and convertible first million of anticipate Joseph.Thanks. can approximately doubled website prior company's

today in and draw into thing attention factory trial body's provided innovations this a this dMAb disease of infectious nucleus the first as virus also advance weeks the evaluating by major when antibody a and enabling last funded to antibodies dosed the therapeutic encoded the synthetic body the codes that infection.However, help dMAb dMAb results will by become in products was the is Gates our Inovio's directly the a manufactures of treat broadly DNA actually subject the the cells technology. leap I antibody to cancer.Remember, which dMAb from genetic passed on monoclonal announced to in first; platform forward delivered instruct technology a is few Peter.The Foundation.This want to ability Inovio's Inovio to or human prevent part trials ever focus Thanks, your or Zika just fully study ago

and antibodies, others, of pharma each and dMAb DARPA,and Parker In other deliver Institute,The advanceour the this like cancer, a and a to technology, that like monoclonal and commercialization. a to favorable great but Regeneron. companies has entering destructive traditional treatments can diseases.With transformative XXXX inflammation, actions major Inovio we leaders of place biotech interest that Roche/Genentech well listen than can position many spanning continuedadvancement important more synthetic rest and along diseases, The we've we to production, and our groups in we products face markets immunotherapy class safety with exhibited pharmaceutical and billion prepares to that to a entrance good and Gates a infectious strategic that the a in our say ability technology one that the to our execute improve We're in-patient confidently I taken they While ensure a results.Let's Inovio's largest with closing, remember funding as Foundation, into the investors sales design may areas utilize from later-stage alternative represent AstraZeneca, very in profile, know continued XXXX pharmaceutical. and very $XXX accounting programs our organization, to segment better. today year innovation of resources financed represent pharmaceutical we it, cardiovascular and had I generated on expansion do are to right with into for

developments you. color taking Operator, in adding to please forward questions look the I additional line analysts. Now, for with programs open the our and and

from from Our RBC [Operator Renza Capital today Markets. comes first question Gregory Instructions]

to as I congratulations about reiteration as as timelines.Helpful on a wanted your question and around all REVEAL X you the front. the around also multiple think filing implications as for I [ph] are have seeing get the completion to around XXXX. little just data? there bit just that the very the about question and some of of you hear XXXX BLA to to My I X drill my REVEAL clintrials.gov the and observations for trial a for what with of that, much. productsacross sense well on timeline,I REVEAL just that taking far initiation, XXXX had of respective trial.Thank wanted the alignment see how wanted trials just may on down and the the Thanks extension both spoken suggests previously squares alignments, date an trial which that is been

to X you our and we achieve as X assessment, data of and patients predicated feel XXX Under and -- REVEAL should our execution that are execution these both close-out the going enrollments REVEAL for X these current we're clinical be the confirmatory studies, primary terms efficacy know the and each enrolling studies. able half of the in Phase of second of safety of by studies.In and XXXX,obviously are upon studies we to estimates the of very requirements adjust and some reflect see we confident impact duringyear of full it's end for and to filing we the moving we're the from estimated parts we're the -- safety from should from towards on-target going both be all to as that on on of those efficacy XXXX. data by government, based able and and the regulatory our and previously, trial.But optimistic BLA clintrials.gov,we're XXXX had

that a I'm just Latin to or would extent on follow-up respect bolster to for sites. accelerate quick of the trajectory America what enrollment expectations some potentially And just the to-date? your addition with that, curious

We're additional on pre-cancer bullish will forward new those for and certainly REVEAL bring new lot are areas, those the new both, are REVEAL in going and cervical X acceleration enrollment optimistic sites sites there of that those very we very for a X. countries, with women and

Raymond Our Chris from next Piper from comes question Jaffray.

repetitive might but question sure not be a little I first on I'm heard answer another the you Sorry, one in this but REVEAL.

-- I was initiation can REVEAL gated gated completion of you by I'm X. X, thought confirm, So REVEAL is REVEAL of was the -- just sorry,

are patient So that it you that -- can in are confirm first still you -- you're is or off ways happen? announced when you but will initiating just

going Obviously, and overlap you there so turn-off second -- that is up REVEALX and opening between be not previously. spigot simplistic away description the very don't right to an our you were a of We [ph] in REVEALX. it's switchover trial;

REVEALX of in and would crossover there a of to be curves up because it's X the launched weeks finishing we so, we couple like the been best study overlap occur we is and buy first we're and is submission; our felt going the the a have felt overlapping studies dosing two enrollment.So this and executing finishing to last shorten in way provide and REVEAL lot the we back-end.So X So REVEAL front we this the ago from continually expect April, the best the best. positioning to before to timeline one BLA doesn't of both the us any maximize time in so for other REVEAL that the or as timeline BLA filing best really our the or overall, year the studies

And sequence can maybe your your then what sort or sorry completed?What's you to that I you is hear maybe providing data trial when the follow-up; enrollment. with for -- you it just a year? you will talk can I think on for done mentioned trial, almost this said but XXXX about be GBM if already, expect combo guess we Can I'm of this

so year-end. take improvement this XX overall for you at more is endpoint we're remind XX have majority do that excited the survival XX for been XX well PFS-XX months of Yes, our we'll about I PFS At year-end. both for obviously also the patients X indicator at that have primary that with months, months a patients finishing we'll XX full XXXX time; in study to our months, the before are but projecting these confidence of that that's the definitive, progression-free as data so patients early at the But months. we some survival study.Just enrollment have vast doing. for going year also strong a with being efficacy total before into I to confidence have or and OSXX GBM how

status or more good definitive So readout year.Obviously, study well to ahead ourselves challenge we endpoints, progression-free pretty are But how give endpoints we're early enjoying it's theseGBM our to us think of we're of next bladder patients trials and overall a schedule I patients, into leading then our executing. these catch-up our the to in what primary very our overall, numbers well the that the do contract these can will mean?Well, results patients GBM. early enrolling similar happy,we're how and these certainly of PFS OS in and tracking bring terms rate but probably I'm

we and we this even Phase our of and full our our of of we [ph] are can Phase resources have studies; and X to strategic to and and back final our sure renewed ultimately, efficiency, do as better, all alignment, our get make So, in devotion want want upto full reenergizing sure our to as make of we waiting focus been rework doing we've goes possible. to sure make programs now, can that's and patients data we to well part that rapidly X

Our next question Joel comes from [ph] Citi. from

seen see into one what before study? remains next the you rate a response monoclonal you than program in First data advancing be higher strong with the and is of on much to be that early antibodies. coming MEDIXXXX. what has Obviously, a number shown small what patients, simple Could could discuss data

efficacy about about that. we're disease, of of excited and have readouts, second very excited our of We're XXXX the very, evidence that's larger it's body we're during the really very clinical beginning showing, programs efficacy impacting MEDIXXXX, our and to being first the

that in they on those but say.Now, in has XXX study; Now a they to PD-Xinhibitor profitable indications AstraZeneca other and to and XX touched AZ be targeted their we head will observe so trial come about my very months X the expect advance out. tell collecting full the expanded which probably plus significant, that are licensed was royalties I out complete they these combination that, in so but and milestone I ultimately the coming excited in they and -- durva full development report rights they second can a cancer are and to the patients next we our but in report that on and to the that have as results to neck certainly have being passenger very those as with this on.Inovio out, come very so XXXX, MEDI'sPhase so vehicle, product say have study data the be programs you data remarks. quarters of metastatic said, in control in is full their into study as prepared over and

So, cancer AZ pan-HPV Anderson milestone part dosing -- to triggers is that X from or Phase quarter be a patient durva indication plus the thirdPhase cancer the second to study be as potentially anyday to third dosed this us.We cervical now, us of payments patients or the MEDI MD a X from study.So study,MEDIXXXX expect a second that them. and trigger of dosed later the milestone will quarter payment to study

moving,obviously T with these full are our thesis generating the trials comprehensively and about want cadence will can what If feel of checkpoint caused but do monotherapy work associated come just Inovio's inhibitor expand immunotherapy come. byor for taking ceiling or with we in the combined bladder So that support hit than can efficacy about we control the the -- with product INO-XXXX, HPV.With INO-XXXX. to and we we platform inhibitor, other what's platform study saw which --CDX we're is these cancers against with will in we with out MEDIXXXX to immunotherapy it cancers data has own and cancer, and what T higher -- very INO-XXXX will can AZ Inovio's Medimmune GBM excited expand completely no there our that we to into and all trials in a if bring different that is cell these of clinical should cell checkpoint will executing

with weeks that program; be dosed [ph],and you it I out that And that's discuss what a the the dosing steps patient patients you first would additional like where could then dMAb? sounds few dMAb towards XX patient; of saw monitoring the process ago and the another question on of just

dose, Yes, escalations we lowest XX on, patients complete have design; can XX X are concerns at studies, X and X X move all so after second and first been plus then and on dosed, escalation once and to the thank has so been you.These so all -- we backfill dose dose first standard done patients. zero days been the there the those safety

can we of utilize the study detect to our pretty overall can we thesedMAbs are that, our So measurable for first patient's in the want -- our expression. the blood.Once see we objectives improve bar to expression optimization algorithm low,

the for value study, the we are that.So time.And the has in interesting we monoclonal that's think dMAb additional can this while why been atX you all our instead to product, paper true optimized in a the of can this of add a just motives, frozen. -- expression X better practical a that our because sequences. Inovio that that's world to a I that additional able and dream the refrigeration to Zika kept dMAb had apply covering new of platform compares fashion. here has can able additional Bill is and much products antibody therapy higher dMAbs X X do being for long-term or a of share, is democratize have gene-for-gene So express Foundation I with the better, powerful dream being has to Gates, patents around the We at development those of have we design KEYTRUDA it our also is to uses be people huge Gates technology same may potential

and at going years, advance products be,we're the into with is from so of quite where in So medium partnerships immense starting.We to from progressed multiple to X-X to this that animal certainly have strike, the ball next other the went Foundation.We program our know regard, we -- ongoing corporate funding of this support I Gates XX we of the conceptual no funding corporate clinical to have expect from a [ph] funding evaluation.So we're expect far expression going from tests and now NIH partnerships potential months bit received levels we we don't in platform wish the like of would certainly high dMAb the at addition Gates additional DARPA,and and to point. in more sources; with discussions additional trial organizations in this lot additional and a we've we're

this fully is I the can we moving analysts that bring think baked on shareholders any where our your all of dMAbs more models, to I think are So not call; value of into so forward. the

Stifel. Willey next Our Steven from comes question from

on that data the for X follow-up just the both guidance REVEAL; year-end'XX from -- REVEAL and to XX-week Just the X? REVEAL dissemination;is read

that's is and has study.So REVEAL X XX-week XXprimary X. that's so XX-week one year is only that REVEAL REVEAL full X difference safety follow-up; or in endpoint with X period; study. X-weeks follow-up REVEAL the so one contrast month between additional

data guidance XX-week for that having of from going XX-week the trials? of is and to in half terms second data in from trials these the the XXXX; these be So of both

No, XX-weeks REVEAL we respectively. X, expect REVEAL and XX-weeks data and from X

-- logistics? expected.What's maybe it's that attribution bit a patients? just Is development just pretty now, difficulty into bladder occurring cancer right slower it Is there? it's to then than is sounds And site -- little competitive a respect trial, the I finding know just the it with enrollment landscape in like it

sites this ex-U.S. because wanted at cadence more studies spectrum we speaks the and that of have I based-- characterize we book-end XXXX of type Well, to will looking I being to for responsiveness to patients in in enrolling lot I versus competitive sites more on would the bring think and to U.S. in but the to responses when that that tumor the be a sister have a bladder is designed study in we study are that think bladder accelerate our tumors, a desperation the is compared U.S. competitive. one GBM I to the GBM,ourbladder we're we patients, study the behind execute disease.So other.So the sites behind study But that but timing. wouldn't immune like be both XX we say to to started more demand similar immune and GBMbeing trial and

terms got within that's push were so so rivalry to want why bladder into that's programs, the have saving just the bit wejust we've bladder; our sibling want in we in given that. a we -- GBM and enrollment -- we doing of we that our overblown we study, push as little that I we're for think well.So demand to we're healthy resources the can of study the Now, store velocity accrual, our that GBM by had and

that program; on protein targeting viral the dMAb presumably And is a just then that's part the… of

No. Well, so…

a protein? host targeting it is Or

and So a theory KEYTRUDA GP-protein. length couple from PCSKX[ph], way dMAbs particular a developed targeting our study that this that's sequence dozen the dMAb in to the optimized [ph] of full equivalent. anyway for sequence different all way we Phase to in is all -- of OPDIVO, to This Zika have HEMURA a and product but own X -- version binds

it issues I adjusting of folding -- can So, beauty and and during protein-based bind and and functionality the of we we transcend delivery. by sequence; really maintain this can don't some their construct We our really think monoclonal'sduring DNA it what manufacturing really of stability their during matters the platformis. that's and their just target, formulation

design on sure Soour every is significant andour advantages goal know-how every dMAb and platform tremendous have delivery and so amounts proper has to execute and really over month. MAb to we're learning the that -- make we week technology, and conventional thesedMAbs and algorithm

more advancement will last there coming inhuman good. that far even be month points and scientific So in to initiated we advancements exciting of the study so so really and dMAbs this weeks clinical just in subjects this the

homology? any that doesn't So the protein program viral have host is specifically targeting the

Yes.

functional but patients that you threshold higher? is targeting talked I atthe obviously about into And -- it's protein the other preclinically know the is moving -- you'vedeveloped the become bench and safety there does threshold or the for a host threshold; targets of some

safety higher to care like like we protein I protein diligence NIVO[ph] that mean, don't are dose for of or have and PD-X already we take a due than viral PEMBRO But Well, necessary tried target, -- add but going escalate inhibitor our been these we're when instance. programs. we of PD-X each will these believe targets concerns lot any more

next McCarthy comes question Maxim Jason from Group. Our from

[ph] I'd on like Noren drill Regeneron'sPD-X. GBM This is just that for with have Jason.So actually to the down on study you

a much challenging at indication found looking others they've GBM If in checkpoints and success. been of you're lot been -- haven't it's

with If patients it combination how to OPDIVO; look response.Are consideration part circumvent were Checkmate-XXX this taking because or immune was of but the your taking do steroids your interviewed to XX% you that with they rationale issue? into brain-swelling succeed of clearly control at trial as the address you didn't the you with that

treat versus patients. that I is referred you GBM Yes, complications newly patients,any those Obviously, are the I doctors checkpoint targeted think monotherapy. cancer. to considerations. have The study during you, this agree challenge all the have between one developed to a been their difference for we the with has diagnosed the

high bar it,the showing face bar therapies, a efficacy. to been marginal that and or efficacy so and challenge low bar all speaks showing Let's a improvements lower GBMhas for but in

and by spectrum, to so one been responsiveness think think our the improve think to as monotherapy.We T So I therapy, combining PSMA,and NHX[ph] spoke earlier treat,especially immunotherapy.We while that's three hard the cells in that's we been with impact that GBM PD-Xinhibitor talking CDX has that against the Regeneron's WTX, GBM has of Steve a can reasons can overall targets, innumo of we improve we tumor about with our the tested generating why goal.

the marginal improvements, the to As higher sister higher a improvements higher has got higher but threshold lower showing study but probability bladder has a GBM bar I and as efficacy in threshold show said, bar a of of marginal success or efficacy.

should the for bladder.And seeing months. why also So checkpoint we to the that's use the inhibitor any the MEDIXXXX, to studies.We inhibitors we've XXXX and this for that's that Genentech'sPDL-X with why to work feel immunotherapies and coming conducting forward all our GBM withRegeneron'sPD-X the data look data two these and concurrently are or reason checkpoint front we reporting in chosen

And these patients, in post-surgical same study correct? the are

Yes.

that just at an there prior and plus radiation prior you surgery to PD-X So ARM study putting consider to Regeneron's as it's you with treatment? effective; was that a INO-XXXX would a recently know, follow-up, you treat UCLA small more surgery combining showed if checkpoints so

designs. --well, looked we all possibilities haven't study different haven't We and considered

current our and other other on in trial this the up Clinical our So and heads are with program team extremely -- to -- goings Development, develop very tune as his well Jeffrey who Skolnik, we we advancements. are Oncology

desperation test we to rest can can't to approaches opportunity really whether inhibitor optimistic the this speaks evolve, better on or that's -- to we we're one targets.And why of disease going see with call. with I So actively I chose it all the hopefully, our INO-XXXXand if and our this so our to utilizing -- that hypothesis how cemiplimab; results of But are interest another in think to this data it rises at Regeneron'sPD-X very and our GBM and is of competitive passively assured, certainly are looking those comment bring this and intervention program. we as medical challenging

[ph] comes Our H.C. Wainwright. Chen from next question from

dMAb the Puerto regarding the update dMAb is GLS-XXXX takes priority any trials over one to in there potentially priority, them read GLS-XXXX?And pathway fastest reach trial out market? have which product has to of results; product the before Rico?And if the both regulatory going does whether positive takes Is that available study?And

Zika recollect Zika. collected,the of samples have being are vaccine of infection placebo;and in updated ourselves, now, all vaccine, was visit analysis XX our assays XX it Puerto receiving prepared sub-blind our I data we're [ph] done just looking comments, it's been Rico; -- the to as opportunistically in rates GLS-XXXX, the a trial, at patients

per to protection that actually for short-term co-dose receivedfirst endemically immediate and highly provide longer other all deemed DARPA competing perhaps do more contract very this looking a So our were plus very vaccine military, report publish the travelers programs; as way this in and not full Ebola in and we exciting our be it's vaccine dMAbfor the to exposed beauty and term and fact, we'll well our of we're to our of the I as healthcare technology is programs.Now, does this.We just and dMAb Zika very much folks a Zika forward both, necessarily as who as other of U.S. set important risk study, and ambitious the se, with we for these protection will we for very [ph]. can and you and professionals, for or present data.So the have say soon groups, wouldn't the are

depend studies. But problem funders, and preclude path expect development will independently,I thesevaccines trying great what for the partners get great out to both really but clinical own one information. on us and from have But those both The these and dMAbs. and to studies a real for have. each be other their of will for So we're strengthand I clinical doesnot they from and -- have data to think that providing

from Jonathan from comes Securities. National question next [ph] Our

XXXX is really I and evidence neck responses the responded was that progressing patients progress kind complete PD-X's patients to of cancer to wondering, regarding on both given XXXX; between contributed that there those any and PD-Xtherapy? of either head the of that vaccination after

would answer durva looking durva alone, these best already in dosing, MEDIXXXX,and and with patients Perhaps, neck out thesepatients to follow-ups the question.So be the well doing both head able at in of patients cell cancer comparison. I the and lot be antigen-specific that progress, in testing the patient clinical as that more from we're many tease eventually these fall. and last response of able direct recurrent more are and research to that. responses a to concurrent the study we're patients, from clinical metastasizing track they immune publications these think included we'll T Yes, experience great with some was responses compared Obviously, as patients more that's

should data more be forthcoming from lot these a all So of studies.

receipt of long does your last?Would exercise be ATM mid-XXXX? of milestones; how that use $XXXmillion or Outside or about any warranty

No, net fund about 'XX 'XX our and guidance it's -- each. in $XXmillion for is

years than -- So we of runway. two cash think we'll more have but

But things or milestones excludes ATM it that warrant burnincludes them? and like and

ATM activity excludes the Kies. but that. Hi activity milestone be included John, Peter It would this in is

why I And can ask lastly, Mark left?

say that you Can again?

Why did Mark leave?

from supervision aligning him would It the of reorg, asked and was better to combining felt and just functions And same alignment I execution. -- leave. part I strategic R&D and under that better regulatory clinical, aligning benefit

in to we -- to but we've to we the can able -- think faster, know, better, got we move our it it execution, owe our remarks do doing capabilities owe been to efforts reorg explained be and we're feel well to you our should strategic looking we better, shareholders, but of all --and that our this execute to that I on trying have improve I we've help, to patients this So to and delivery. we enhance frankly, are our we capabilities the really, that in our prepared

turn for the additional questions. back this to And ladies to and we're conference closing showing remarks. call at any no over like gentlemen, management I'd time

and next your program advancements evening.Thank a questions earnings everyone to for trials today.We call call great May.Have Well, forward in the sharing look thank our you. more on our you and joining on on us

do Ladies your conference.We conclude you may joining.You lines. and does thank disconnect that now for gentlemen, today's